M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Europe.
Flawless balance sheet with reasonable growth potential.
Share Price & News
How has M1 Kliniken's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
1 Year Return
Return vs Industry: M12 exceeded the German Healthcare industry which returned -29.7% over the past year.
Return vs Market: M12 underperformed the German Market which returned 2.9% over the past year.
Share holder returns
Price Volatility Vs. Market
How volatile is M1 Kliniken's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StIs M1 Kliniken AG's (ETR:M12) 11% ROE Better Than Average?
3 weeks ago | Simply Wall StHere’s What M1 Kliniken AG’s (ETR:M12) Return On Capital Can Tell Us
1 month ago | Simply Wall StA Look At M1 Kliniken AG's (ETR:M12) Exceptional Fundamentals
Is M1 Kliniken undervalued based on future cash flows and its price relative to the stock market?
Discount to future cash flow value
Intrinsic Value Based on Future Cash Flows
Undervalued: M12 (€12.4) is trading below our estimate of fair value (€16.87)
Significantly Undervalued: M12 is trading below fair value, but not by a significant amount.
Price Based on Earnings
PE vs Industry: M12 is poor value based on its PE Ratio (29.2x) compared to the Healthcare industry average (25.7x).
PE vs Market: M12 is poor value based on its PE Ratio (29.2x) compared to the German market (19.7x).
Price Based on Expected Growth
Low PEG Ratio: M12 is poor value based on its PEG Ratio (1.1x)
Price Based on Value of Assets
PB vs Industry: M12 is overvalued based on its PB Ratio (3.2x) compared to the DE Healthcare industry average (1.5x).
How is M1 Kliniken expected to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Estimates
Future Annual Growth Analysis
Earnings vs Savings Rate: M12's forecast earnings growth (27.4% per year) is above the savings rate (0.2%).
Earnings vs Market: M12's earnings (27.4% per year) are forecast to grow faster than the German market (12.8% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: M12's revenue (17.3% per year) is forecast to grow faster than the German market (5% per year).
High Growth Revenue: M12's revenue (17.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Estimates
Future Return on Equity
High Future ROE: M12's Return on Equity is forecast to be low in 3 years time (16%).
How has M1 Kliniken performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: M12's earnings have declined by -0.7% per year over the past 5 years.
Accelerating Growth: M12's earnings growth over the past year (32.6%) exceeds its 5-year average (-0.7% per year).
Earnings vs Industry: M12 earnings growth over the past year (32.6%) exceeded the Healthcare industry 19.5%.
Return on Equity
High ROE: M12's Return on Equity (10.7%) is considered low.
Return on Assets
ROA vs Industry: M12 has a higher Return on Assets than the Healthcare industry average last year.
Return on Capital Employed
ROCE Improving: M12's Return on Capital Employed has declined over the past 3 years.
How is M1 Kliniken's financial position?
Financial Position Analysis
Short Term Liabilities: M12's short term assets (€42.5M) exceeds its short term liabilities (€5.5M)
Long Term Liabilities: M12's short term assets (42.5M) exceeds its long term liabilities (11.4M)
Debt to Equity History and Analysis
Debt Level: M12's debt to equity ratio (0.2%) is considered satisfactory
Reducing Debt: M12's debt to equity ratio has reduced from 15.5% to 0.2% over the past 5 years.
Debt Coverage: M12's debt is well covered by operating cash flow (1148.9%).
Interest Coverage: M12 earns more interest than it pays, so coverage of interest payments is not a concern.
Inventory Level: M12 has a high level of physical assets or inventory.
Debt Coverage by Assets: M12's debt is covered by short term assets (assets are 361.385470x debt).
What is M1 Kliniken's current dividend yield, its reliability and sustainability?
Expected Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Dividend Yield and Payments Analysis
Notable Dividend: M12's dividend (2.42%) is higher than the bottom 25% of dividend payers in the German market (1.46%).
High Dividend: M12's dividend (2.42%) is low compared to the top 25% of dividend payers in the German market (3.86%).
Stable Dividend: Whilst dividend payments have been stable, M12 has been paying a dividend for less than 10 years.
Growing Dividend: M12 has only been paying a dividend for 3 years, and since then payments have not increased.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (70.8%), M12's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: M12's dividends in 3 years are forecast to be covered by earnings (53.8% payout ratio).
What is the CEO of M1 Kliniken's salary, the management and board of directors tenure and is there insider trading?
Average board tenure
Patrick Brenske 0
Mr. Patrick Brenske has been the Chief Executive Officer of MPH Mittelständische Pharma Holding AG since January 23, 2009 and has been its Member of Management Board since 2009. Mr. Brenske serves as Chief ...
Board Age and Tenure
Experienced Board: M12's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Walter von Horstig
Member of Management Board
- Tenure: 2yrs
CEO & Member of Management Board
- Tenure: 0yrs
Albert Wahl (59yo)
Chairman of Supervisory Board
- Tenure: 2.3yrs
Sabine Meck (64yo)
Member of Supervisory Board
- Tenure: 4.3yrs
Deputy Chairman of Supervisory Board
- Tenure: 2.3yrs
M1 Kliniken AG's company bio, employee growth, exchange listings and data sources
- Name: M1 Kliniken AG
- Ticker: M12
- Exchange: XTRA
- Founded: 2007
- Industry: Health Care Facilities
- Sector: Healthcare
- Market Cap: €217.000m
- Shares outstanding: 17.50m
- Website: https://www.m1-kliniken.de
Number of Employees
- M1 Kliniken AG
- Grünauer Strasse 5
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|M12||DB (Deutsche Boerse AG)||Yes||Bearer Shares||DE||EUR||Sep 2015|
|M12||XTRA (XETRA Trading Platform)||Yes||Bearer Shares||DE||EUR||Sep 2015|
M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Europe. It develops and markets pharmaceutical, medical, and medical technology products for ae ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2019/10/13 23:43|
|End of Day Share Price||2019/10/11 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.